Physician profile
John C Morgan
NPI 1023127024
$714,678.07
in general payments reported to CMS, 2019-2025
50 companies · $136K in 2025
The $136K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111K · 2020: $102K · 2021: $74K · 2022: $108K · 2023: $57K · 2024: $126K · 2025: $136K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $138K · Honoraria: $101K · Consulting Fee: $38K · Travel and Lodging: $23K · Food and Beverage: $13K · Education: $5,798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $138,200.00 |
| Honoraria | $101,035.50 |
| Consulting Fee | $38,496.88 |
| Travel and Lodging | $22,803.91 |
| Food and Beverage | $13,016.94 |
| Education | $5,798.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $274,760.84 | 2019-2025 | Rytary, Crexont |
| Kyowa Kirin, INC. | $184,128.30 | 2019-2024 | Nourianz |
| Lilly USA, LLC | $97,898.03 | 2024-2025 | Kisunla, Amyvid |
| Acadia Pharmaceuticals INC | $44,148.11 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $22,705.27 | 2019-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $22,300.31 | 2020-2025 | Skyclarys, Spinraza, Leqembi |
| Sunovion Pharmaceuticals INC. | $17,400.96 | 2020-2022 | |
| Abbvie INC. | $15,968.51 | 2019-2025 | |
| Acorda Therapeutics, INC | $11,003.16 | 2019-2024 | Inbrija |
| Lundbeck LLC | $6,344.72 | 2019-2024 | Rexulti |
| Eisai INC. | $5,452.84 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $4,356.91 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $3,048.19 | 2019-2021 | |
| Avion Pharmaceuticals | $1,779.58 | 2021-2023 | Dhivy |
| Otsuka America Pharmaceutical, INC. | $984.46 | 2023-2024 | Rexulti |
Show all 44 companies
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.